DCF Advisers’s Kyntra Bio KYNB Stock Holding History

DCF Advisers’s Portfolio KYNB Stock Details KYNB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q2	–	Sell	-685	Closed	-$594K	–	103
2021 Q1	$594K	Sell	685 -555	-45%	-$591K	0.26%	71
2020 Q4	$1.15M	Buy	1,240 +280	+29%	+$294K	0.47%	43
2020 Q3	$987K	Buy	960 +580	+153%	+$624K	0.5%	44
2020 Q2	$385K	Sell	380 -160	-30%	-$149K	0.22%	62
2020 Q1	$469K	Sell	540 -160	-23%	-$159K	0.31%	48
2019 Q4	$751K	Buy	+700	New	+$715K	0.48%	43

Other funds holding KYNB

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

First Trust Advisors Wheaton, Illinois $140B AUM 27.84% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

DCF Advisers's KYNB Position: Q2 2021 in Review

DCF Advisers sold out of Kyntra Bio (KYNB) in Q2 2021, closing a stake of 685 shares — an estimated $594K sold.

DCF Advisers first reported a position in KYNB in Q4 2019 and held it in 6 quarters. The position peaked at $1.15M in Q4 2020. 174 funds tracked by Wall St. Rank hold KYNB as of Q2 2021.

DCF Advisers reported no remaining Kyntra Bio position as of Q2 2021 after selling out during the quarter.
DCF Advisers sold 685 Kyntra Bio shares in Q2 2021, an estimated $594K.
DCF Advisers first reported a position in Kyntra Bio in Q4 2019 and held it in 6 quarters.
DCF Advisers's Kyntra Bio position peaked at $1.15M in Q4 2020.
174 funds tracked by Wall St. Rank held Kyntra Bio as of Q2 2021.

Based on DCF Advisers's 13F filing for Q2 2021, filed 13 Aug 2021.